Vaishali Pharma Limited share price

Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, antimalarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides pharmaceutical formulations, including antibiotics, antibacterial, anti-platelet, laxative, anti-ulcer, enzymes, anti-asthmatic, anti-malarial, anti…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: VAISHALIISIN INE972X01022

16 Oct 2026, 3:29 PM IST₹7.81▲ 0.02 (0.26%)

Market Cap₹ 102 Cr.
Current Price₹ 7.81
High / Low₹ 11 / 5
Stock P/E—
Book Value₹ 5
Dividend Yield0.00 %
ROCE9.8 %
ROE6.00 %
Face Value₹ 2.0

More figures (10)

EPS (TTM)—
Price / Book1.47
OPM5.4 %
Debt / Equity0.27
Sales growth (4Y)18.0 %
Profit growth (4Y)-15.2 %
Promoter holding—
EV / EBITDA30.6
Beta0.36
All-time high₹ 25

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
VAISHALI	-10.02%	-0.89%	+19.24%	-9.40%	-27.08%	-16.26%	+16.32%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Vaishali Pharma Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹102 crore.
Revenue grew 18.0% a year over the last 4 years, profit -15.2% a year.
Return on equity was 6.0% and return on capital employed 9.8% in the latest year.
Debt was 0.27 times shareholders' equity.
The share price is 30.0% below its 52-week high and down 27.1% over one year.

Pros

Promoters have raised their holding by 4.99 points over 3 years, to 31.61%.
Borrowings are moderate at 0.27 times shareholders' equity.

Cons

Return on equity has been low: 3.1% on average over the last 3 years.
Other income makes up 66% of profit before tax.
The company has not paid a dividend recently.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Vaishali Pharma Limited

Employees: 30
Head office: Mumbai

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Vaishali Pharma	7.81	—	102	0.00	2	—	23	—	9.8	6.0	1.47	5.4	0.27	—	109	18.0
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	786	-39.18	7,119	2.33	14.9	11.8	3.11	17.5	0.02	31.13	28,163	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	574	29.12	4,031	12.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 59 Co.	1,712.85	34.3	11,303	0.18	680	14.29	6,020	18.48	14.6	13.2	4.00	15.2	0.24	54.79	20,499	11.4

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	33	25	27	23
	32	23	27	21
Material Cost %	89%	85%	91%	85%
Employee Cost %	2%	3%	3%	3%
Other Expenses %	5%	6%	7%	5%
Operating Profit	1	2	-0	1
OPM %	4%	6%	-1%	6%
Other Income	1	1	1	1
Interest	0	1	1	0
Depreciation	0	0	0	0
Profit before tax	2	2	0	2
	28%	28%	-48%	14%
Current tax	0	0	0	0
Deferred tax	0	0	-0	-0
	1	1	0	2
Profit from associates	0	0	0	0
EPS in Rs	0.05	0.10	0.03	0.12
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	13	13	28	32	18	21	28	32	24	33	25	27	23
YOY Sales Growth %	31.85%	-4.51%	38.88%	23.47%	34.70%	65.42%	0.07%	-0.46%	31.35%	60.91%	-11.69%	-16.49%	-3.60%
	11	10	25	39	16	18	27	38	22	32	23	27	21
Material Cost %	74%	66%	86%	100%	80%	81%	85%	95%	84%	89%	85%	91%	85%
Employee Cost %	4%	5%	2%	2%	3%	3%	2%	2%	3%	2%	3%	3%	3%
Other Expenses %	5%	9%	2%	19%	4%	5%	8%	21%	7%	5%	6%	7%	5%
Operating Profit	2	3	3	-7	2	2	1	-6	1	1	2	-0	1
OPM %	17%	21%	11%	-21%	13%	12%	5%	-19%	6%	4%	6%	-1%	6%
Other Income	0	0	0	1	0	1	1	1	1	1	1	1	1
Interest	0	0	0	0	0	0	0	0	0	0	1	1	0
Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0
Profit before tax	2	2	3	-6	2	3	2	-6	2	2	2	0	2
	25%	28%	26%		25%	25%	25%		26%	28%	28%	-48%	14%
Current tax	1	1	1	-2	1	1	0	-1	0	0	0	0	0
Deferred tax				-0				-0	0	0	0	-0	-0
	2	2	2	-5	2	2	1	-4	1	1	1	0	1
YOY Profit Growth %	4.94%	-14.57%	-20.66%	-1,175.20%	7.13%	15.54%	-31.70%		-24.70%	-39.82%	-9.79%		16.45%
EPS in Rs	0.08	0.08	0.10	-0.22	0.07	0.08	0.05	-1.59	0.05	-0.25	0.10	0.02	0.11
Raw filing

Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2026	TTM
Sales	109	108
	105	104
Material Cost %	87%	88%
Employee Cost %	3%	3%
Other Expenses %	6%	6%
Operating Profit	4	4
OPM %	4%	4%
Other Income	4	4
Interest	2	2
Depreciation	1	1
Profit before tax	5	5
	25%	21%
Current tax	1
Deferred tax	0
	4	4
Profit from associates	0	0
EPS in Rs	0.32	0.30

Compounded Sales Growth

TTM:: 0%

Compounded Profit Growth

TTM:: 0%

Stock Price CAGR

5 Years:: 16%
3 Years:: -16%
1 Year:: -27%

Return on Equity

4 Years:: 6%
Last Year:: 6%

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	60	54	76	70	86	99	109	108
YOY Sales Growth %		-10.50%	41.00%	-8.12%	23.85%	14.77%	9.84%
	59	51	69	61	85	99	105	104
Material Cost %	85%	86%	84%	78%	86%	87%	87%	88%
Employee Cost %	3%	3%	3%	3%	3%	3%	3%	3%
Other Expenses %	10%	6%	4%	5%	10%	11%	6%	6%
Operating Profit	1	3	7	9	1	0	4	4
OPM %	1%	5%	9%	13%	1%	0%	4%	4%
Other Income	2	2	2	2	2	3	4	4
Interest	2	3	2	2	2	2	2	2
Depreciation	0	0	0	1	1	0	1	1
Profit before tax	0	1	6	9	1	1	5	5
	59%	26%	30%	25%	22%	33%	25%	21%
Current tax	0	0	2	2	0	0	1
Deferred tax	-0	-0	-0	0	-0	-0	0
	0	1	4	7	1	1	4	4
YOY Profit Growth %		3,089.94%	284.56%	64.10%	-89.11%	13.69%	393.27%
EPS in Rs	0.00	0.05	0.19	0.31	0.03	0.16	0.31	-0.02

Compounded Sales Growth

5 Years:: 15%
3 Years:: 16%
TTM:: 3%

Compounded Profit Growth

5 Years:: 31%
3 Years:: -15%
TTM:: 967%

Stock Price CAGR

5 Years:: 16%
3 Years:: -16%
1 Year:: -27%

Return on Equity

4 Years:: 6%
Last Year:: 6%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	11	11	26	26
Reserves	30	32	39	43
	15	13	12	19
Long term borrowings	5	4	4	6
Short term borrowings	8	9	7	13
	24	24	33	35
Trade payables	18	19	27	21
Current liabilities	32	33	40	48
Total Liabilities	79	80	110	123
	2	1	1	1
Gross block	3	3	3	4
Accumulated depreciation	1	2	2	2
Goodwill & intangibles	1	1	1	1
	77	79	109	122
Inventories	3	0	5	3
Trade receivables	54	49	47	51
Cash & equivalents	1	1	2	1
Current assets	73	75	104	113
Total Assets	79	80	110	123

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1	1	-18	0
Profit for the year	7	1	1	4
Working capital changes	-7	-4	-26	-9
Direct taxes paid	-2	-2	-0	-0
	0	1	-0	-5
Fixed assets purchased	-0	-0	-0	-0
	-2	-1	18	5
Interest paid	-2	-2	-1	-2
Net Cash Flow	-0	1	0	-0
Free Cash Flow	1	1	-18	-0

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	16.3%	1.7%	1.5%	6.0%
ROCE	—	23.7%	6.8%	4.7%	9.8%
Operating margin	—	14.1%	7.8%	6.0%	5.4%
Net margin	—	10.3%	0.9%	0.8%	3.8%
Debt / equity	—	0.36	0.31	0.19	0.27
Current ratio	—	2.27	2.25	2.61	2.34
Debtor days	—	307	221	174	177
Inventory days	—	20	2	20	13
Days payable	—	120	95	116	81
Cash conversion cycle	—	207	128	78	109
Working capital days	—	232	185	240	225

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 31.61%
Public 68.39%

%	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	26.62%	26.62%	26.32%	26.32%	26.32%	26.32%	26.32%	26.32%	26.32%	31.61%	31.61%	31.61%
	73.38%	73.38%	73.68%	73.68%	73.67%	73.68%	73.68%	73.68%	73.68%	68.39%	68.39%	68.39%
Retail (up to ₹2 lakh)	31.94%	29.88%	29.51%	28.51%	33.48%	38.44%	32.88%	33.84%	32.51%	26.92%	26.95%	28.14%
HNIs (above ₹2 lakh)	30.06%	31.06%	33.42%	37.60%	31.50%	26.48%	32.36%	32.04%	34.74%	35.83%	35.37%	34.66%
NRIs	0.36%	0.33%	0.44%	0.46%	1.11%	1.22%	0.94%	0.44%	0.45%	0.35%	0.34%	0.35%
Bodies corporate	2.97%	5.06%	3.05%	2.36%	5.43%	5.50%	5.26%	4.65%	3.19%	2.42%	2.69%	2.61%
No. of Shareholders	9,983	9,181	9,390	9,479	18,983	27,546	28,874	28,682	27,752	27,148	26,534	26,671

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Credit RatingVaishali Pharma Limited has informed the Exchange about Credit Rating12-Apr-2023

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 1 Jan 1970
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Vaishali Pharma Limited

What is the share price of Vaishali Pharma Limited today?

Vaishali Pharma Limited (VAISHALI) last traded at ₹7.81 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Vaishali Pharma Limited?

About ₹102 crore at the latest price.

What is the P/E ratio of Vaishali Pharma Limited?

The P/E is not available (for example when earnings are negative).

Is Vaishali Pharma Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Vaishali Pharma Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Vaishali Pharma Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Vaishali Pharma Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Vaishali Pharma Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next